Literature DB >> 18354037

BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma.

Alejo A Morales1, Delia Gutman, Kelvin P Lee, Lawrence H Boise.   

Abstract

The use of arsenic trioxide (ATO) to treat multiple myeloma (MM) is supported by preclinical studies as well as several phase 2 studies, but the precise mechanism(s) of action of ATO has not been completely elucidated. We used gene expression profiling to determine the regulation of apoptosis-related genes by ATO in 4 MM cell lines and then focused on Bcl-2 family genes. ATO induced up-regulation of 3 proapoptotic BH3-only proteins (Noxa, Bmf, and Puma) and down-regulation of 2 antiapoptotic proteins Mcl-1 and Bcl-X(L). Coimmunoprecipitation demonstrated that Noxa and Puma bind Mcl-1 to release Bak and Bim within 6 hours of ATO addition. Bak and Bim are also released from Bcl-X(L). Silencing of Bmf, Noxa, and Bim significantly protected cells from ATO-induced apoptosis, while Puma silencing had no effect. Consistent with a role for Noxa inhibition of Mcl-1, the Bad-mimetic ABT-737 synergized with ATO in the killing of 2 MM lines. Finally, Noxa expression was enhanced by GSH depletion and inhibited by increasing GSH levels in the cells. Understanding the pattern of BH3-only protein response should aid in the rational design of arsenic-containing regimens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18354037      PMCID: PMC2384139          DOI: 10.1182/blood-2007-10-116889

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  70 in total

Review 1.  Cell death: critical control points.

Authors:  Nika N Danial; Stanley J Korsmeyer
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

Authors:  Lin Chen; Simon N Willis; Andrew Wei; Brian J Smith; Jamie I Fletcher; Mark G Hinds; Peter M Colman; Catherine L Day; Jerry M Adams; David C S Huang
Journal:  Mol Cell       Date:  2005-02-04       Impact factor: 17.970

3.  Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo.

Authors:  Ping Zhou; Nagesh Kalakonda; Raymond L Comenzo
Journal:  Br J Haematol       Date:  2005-03       Impact factor: 6.998

4.  A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

Authors:  D Chauhan; M Velankar; M Brahmandam; T Hideshima; K Podar; P Richardson; R Schlossman; I Ghobrial; N Raje; N Munshi; K C Anderson
Journal:  Oncogene       Date:  2006-10-02       Impact factor: 9.867

5.  A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19.

Authors:  Toru Hayakawa; Yayoi Kobayashi; Xing Cui; Seishiro Hirano
Journal:  Arch Toxicol       Date:  2004-11-04       Impact factor: 5.153

6.  Arsenic trioxide inhibits proliferation in K562 cells by changing cell cycle and survivin expression.

Authors:  Xiaofei Wu; Zhichao Chen; Zhongping Liu; Hao Zhou; Yong You; Weiming Li; Ping Zou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

7.  Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.

Authors:  Mohamad A Hussein; Mansoor Saleh; Farhad Ravandi; James Mason; Robert M Rifkin; Ralph Ellison
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

8.  ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

Authors:  M P Kline; S V Rajkumar; M M Timm; T K Kimlinger; J L Haug; J A Lust; P R Greipp; S Kumar
Journal:  Leukemia       Date:  2007-04-26       Impact factor: 11.528

9.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

10.  Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak.

Authors:  Rachel T Uren; Grant Dewson; Lin Chen; Stephanie C Coyne; David C S Huang; Jerry M Adams; Ruth M Kluck
Journal:  J Cell Biol       Date:  2007-04-23       Impact factor: 10.539

View more
  39 in total

1.  Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

Authors:  Vikas A Gupta; Shannon M Matulis; Jason E Conage-Pough; Ajay K Nooka; Jonathan L Kaufman; Sagar Lonial; Lawrence H Boise
Journal:  Blood       Date:  2017-02-01       Impact factor: 22.113

2.  Bcl-xL protein protects from C/EBP homologous protein (CHOP)-dependent apoptosis during plasma cell differentiation.

Authors:  Brian T Gaudette; Neal N Iwakoshi; Lawrence H Boise
Journal:  J Biol Chem       Date:  2014-07-14       Impact factor: 5.157

3.  Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.

Authors:  Katelyn G Ponder; Shannon M Matulis; Sadae Hitosugi; Vikas A Gupta; Cathy Sharp; Francis Burrows; Ajay K Nooka; Jonathan L Kaufman; Sagar Lonial; Lawrence H Boise
Journal:  Cancer Biol Ther       Date:  2016-07-02       Impact factor: 4.742

4.  Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.

Authors:  Jagadish Kummetha Venkata; Ningfei An; Robert Stuart; Luciano J Costa; Houjian Cai; Woodrow Coker; Jin H Song; Kiwana Gibbs; Terri Matson; Elizabeth Garrett-Mayer; Zhuang Wan; Besim Ogretmen; Charles Smith; Yubin Kang
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

5.  Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

Authors:  Alejo A Morales; Metin Kurtoglu; Shannon M Matulis; Jiangxia Liu; David Siefker; Delia M Gutman; Jonathan L Kaufman; Kelvin P Lee; Sagar Lonial; Lawrence H Boise
Journal:  Blood       Date:  2011-06-09       Impact factor: 22.113

6.  Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis.

Authors:  Alejo A Morales; Delia Gutman; Pedro J Cejas; Kelvin P Lee; Lawrence H Boise
Journal:  J Biol Chem       Date:  2009-03-11       Impact factor: 5.157

7.  Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin.

Authors:  Majid Momeny; Majid Zakidizaji; Reza Ghasemi; Ahmad R Dehpour; Maryam Rahimi-Balaei; Yassan Abdolazimi; Ardeshir Ghavamzadeh; Kamran Alimoghaddam; Seyed H Ghaffari
Journal:  Med Oncol       Date:  2009-09-10       Impact factor: 3.064

8.  Functional cooperation of the proapoptotic Bcl2 family proteins Bmf and Bim in vivo.

Authors:  Anette Hübner; Julie Cavanagh-Kyros; Mercedes Rincon; Richard A Flavell; Roger J Davis
Journal:  Mol Cell Biol       Date:  2010-01       Impact factor: 4.272

Review 9.  PUMA, a potent killer with or without p53.

Authors:  J Yu; L Zhang
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

Review 10.  Noxa: at the tip of the balance between life and death.

Authors:  C Ploner; R Kofler; A Villunger
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.